Delving into the Latest Updates on Eculizumab with Synapse

RegulationOrphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (South Korea), Orphan Drug (Australia)

Login to view timeline

Structure/Sequence

Sequence Code 66437L

Source: *****

Sequence Code 66453H

Source: *****

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune condition that mainly affects the eyes and spinal cord, causing serious symptoms such as vision loss, paralysis, and severe pain. This trial compares the effectiveness and safety of five medications commonly used to prevent NMOSD relapses: rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab.
In this study, 160 adults with NMOSD who test positive for a specific antibody (AQP4-IgG) will participate. They will be randomly assigned to receive either rituximab or one of the four other FDA-approved medications. The main goal is to find out which treatment best prevents relapses and has fewer serious side effects. The trial will also measure disability, patient satisfaction, quality of life, and biomarkers that help track disease activity.
Participants will have regular assessments, including medical exams, surveys, and tests for vision, walking ability, and brain function. They will report any side effects or health issues experienced during the study. The trial will last from one to four years for each participant.
This research aims to help patients and doctors make better-informed treatment decisions by providing clear evidence about the best available therapies for NMOSD.

Start Date01 May 2026

Sponsor / Collaborator

The Massachusetts General Hospital

[+1]

NCT07410039

/ RecruitingPhase 4IIT

Eculizumab Add-On Therapy in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Multicenter Prospective Real-World Study

This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage. It comprehensively assesses the clinical outcomes of the patients and aims to compare the clinical efficacy and safety of icoxib as a combined add-on treatment versus simple hormone shock therapy during the acute phase of NMOSD.Using simple hormone shock therapy (IVMP) as the control group, the efficacy and safety of etanercept treatment in the acute attack phase of Chinese patients with AQP4-positive neuromyelitis optica spectrum disorder (NMOSD) were evaluated.

Start Date01 Feb 2026

Sponsor / Collaborator

Chinese People's Liberation Army General Hospital

NCT07413250

/ Active, not recruitingNot Applicable

A Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of International PNH Interest Group (IPIG)-Registry Data

This is a noninterventional registry-based cohort study utilizing data collected on danicopan-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) through the International PNH Interest Group (IPIG) PNH registry. The primary objectives seek to characterize the long-term safety profile of danicopan as add-on therapy to ravulizumab/eculizumab in participants with PNH.

Start Date14 Jan 2026

Sponsor / Collaborator

Alexion Pharmaceuticals, Inc.

100 Clinical Results associated with Eculizumab

Login to view more data

100 Translational Medicine associated with Eculizumab

Login to view more data

100 Patents (Medical) associated with Eculizumab

Login to view more data

2,661

Literatures (Medical) associated with Eculizumab

31 Dec 2026·Hematology

Improvement in anemia and symptoms after switching from crovalimab to iptacopan in paroxysmal nocturnal hemoglobinuria

Article

Author: Onizuka, Makoto ; Ogawa, Yoshiaki ; Nasukawa, Miina ; Ogiya, Daisuke ; Koyama, Seina ; Machida, Shinichiro ; Kawada, Hiroshi ; Shiraiwa, Sawako ; Tomita, Shunsuke ; Endo, Motoki ; Toyosaki, Masako

OBJECTIVES:

Paroxysmal nocturnal hemoglobinuria (PNH) may develop breakthrough hemolysis (BTH) despite C5 inhibition. Although iptacopan, an oral factor B inhibitor, has demonstrated efficacy in phase 3 trials, switching from crovalimab has not been reported. We describe the first clinical case of this switch in a real-world clinical setting.

METHODS:

A 72-year-old man with long-standing PNH received eculizumab followed by crovalimab. Infectious enteritis triggered BTH and worsening anemia during crovalimab therapy. Because anemia persisted after recovery, iptacopan 200 mg twice daily was initiated three weeks after the final crovalimab administration. Clinical symptoms and laboratory parameters were followed for 12 months. This case report complied with the Declaration of Helsinki.

RESULTS:

Hemoglobin increased from 9.6 to 11.6 g/dL within two weeks and remained ≥12 g/dL thereafter. Dyspnea resolved within one week, vitality improved by two weeks, and no BTH or treatment-related adverse events occurred during follow-up.

DISCUSSION:

This case demonstrates the feasibility of switching from crovalimab to iptacopan despite the absence of an established method, and pharmacokinetic considerations guided the timing.

CONCLUSION:

Switching to iptacopan led to rapid and durable improvement in anemia and symptoms, supporting proximal complement inhibition as a valuable option for PNH patients inadequately controlled with C5 inhibitors.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Cost per responder analysis of iptacopan versus eculizumab and ravulizumab in treatment of paroxysmal nocturnal hemoglobinuria: implications for decision-making

Article

Author: Shafrin, Jason ; Muthukrishnan, Sanjana ; Kuypers, Nicholas ; Bilano, Ver ; Than, Kyi-Sin ; Paulose, Jincy

OBJECTIVE:

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and debilitating hematological disease with significant economic burden. Despite the availability of multiple therapies, there is a lack of consensus on optimal treatment strategies among physicians and payers in the United States. This study aimed to evaluate the economic value of iptacopan, a novel oral treatment option, compared to terminal complement inhibitors (specifically, complement component C5 inhibitor or C5i)-including eculizumab and ravulizumab-among patients with PNH who are either (i) C5i-experienced or (ii) complement-inhibitor-naïve.

METHODS:

A cost per responder analysis was conducted based on treatment efficacy from clinical trials comparing iptacopan with C5i treatments. Treatment response was defined as the proportion of patients achieving red blood cell transfusion independence. Treatment costs were estimated as pharmaceutical wholesale acquisition cost and treatment administration costs, accounting for discontinuation. Outcomes evaluated included the number needed to treat to achieve a response and the cost per responder over the treatment duration of 24 weeks.

RESULTS:

Over 24 weeks, the number needed to treat to achieve an additional response was lower for iptacopan than all C5i comparators (C5i-experienced: 1.05 with iptacopan vs. 3.86 with C5is; complement-inhibitor-naïve: 1.02 with iptacopan vs. 1.69 with C5is). Cost per responder was lower for iptacopan than C5i comparators for both C5i-experienced ($264,337 for iptacopan vs. $975,298 for ravulizumab, $1,060,511 for eculizumab, and $744,561-$955,194 for eculizumab biosimilar with 10%-30% discount from eculizumab cost) and complement-inhibitor-naïve patients ($256,754, vs. $428,139 for ravulizumab, $465,546 for eculizumab, and $326,849-$419,314 for eculizumab biosimilar).

CONCLUSION:

Among both C5i-experienced and complement-inhibitor-naïve patients, treatment with iptacopan resulted in higher response rates and lower cost per responder compared to C5is.

01 Jun 2026·IMMUNOLOGY LETTERS

Complement involvement in antiphospholipid syndrome

Review

Author: Darnige, Luc ; Dragon Durey, Marie-Agnès ; Hamidi, Houcine

Antiphospholipid syndrome (APS) is an acquired thrombophilia characterized by thrombotic and non-thrombotic (or non-criteria) manifestations, in the context of persistent presence of autoantibodies targeting phospholipids and associated proteins. The complement system, which shares common actors with coagulation cascade, is nowadays well established to be implicated in APS pathophysiology in different ways. Animal models using knock out strains or complement blocking therapies have helped to decipher the different complement components implicated in the processes of thrombosis and fetal morbidity. In APS patients, complement activation may be assessed through the detection of activation fragments (C4d, C3a, C5a, sC5b9) in plasma and on blood cells surface (C4d, C3d and C5b9) or on APS-affected tissues such as cardiac valves, vessels walls, kidneys and placentae. APS patients are currently treated to avoid thrombosis recurrence by long-term treatment by vitamin K antagonists but various complement targeting molecules are tested in trials or now available and may be of major interest to treat APS patients. Several cases report described the use of eculizumab, an anti-C5 monoclonal antibody, to treat severe forms of APS (recurrent thrombosis, Catastrophic APS) but these studies are not sufficient and need to be more standardized. C4d measurement may be useful to assess classical and lectin pathways activation, C5a may allow evaluating the C5a/C5aR axis activity whereas, associated with sC5b9, it may also assess the terminal pathway activation but also the therapeutic efficacy of complement blocking molecules. Thus, assessment of good complement biomarkers and their kinetics needs to be done to determine personalized therapeutic options.

287

News (Medical) associated with Eculizumab

18 Mar 2026

·www.fiercepharma.com

Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio

Sandoz has inked a deal with Korean biosimilars specialist Samsung Bioepis to commercialize up to five copycats, including a knockoff of Takeda's Entyvio. Sandoz has struck a deal with Samsung Bioepis to partner on up to five biosimilars, with the first being SB36, a copycat of Takeda’s Entyvio (vedolizumab), which is being developed by the South Korea-based biosimilars specialist. Switzerland-based Sandoz gains the right to commercialize the biosimilars around the world, with Samsung Bioepis retaining commercial rights in China, Hong Kong, Taiwan, Macau and its home country. Samsung Bioepis will continue to develop, manufacture and handle the regulatory submissions for the biosimilars. Financial terms of the partnership were not disclosed. The deal, which builds on the existing partnership of the companies, has the potential to expand Sandoz’s biosimilar portfolio to an “industry-leading” 32 assets, the company said in a release. The growing pipeline of products will allow Sandoz to capture a “significant share” of the $320 billion biosimilar loss-of-exclusivity market opportunity in the next decade, the company added.The companies initially got together in 2023, with Sandoz gaining commercial rights to Samsung’s Pyzchiva (ustekinumab), which is a knockoff of Johnson & Johnson’s Stelara. Sandoz launched it in Europe in July 2024 and in the U.S. in February 2025. Three months ago, the companies also paired up on Epysqli (eculizumab), which is Samsung’s biosimilar version of AstraZeneca’s Soliris.With the most recent agreement, analysts from Jefferies credited Sandoz’s “commercial infrastructure” as key to its ability to attract partners. They also noted that the Samsung Bioepis arrangement provides Sandoz with “improved long-term visibility on both R&D productivity and future launch cadence.” Samsung Bioepis plans to expand its biosimilar portfolio by 20 products by 2030, the company said two months ago at the J.P. Morgan Healthcare Conference. In addition to its Entyvio copycat, the company said it will develop biosimilar versions of Regeneron and Sanofi’s Dupixent, Johnson & Johnson’s Tremfya, Daiichi Sankyo and AZ’s Enhertu, Roche’s Ocrevus and Eli Lilly’s Taltz.As for Samsung and Sandoz’s plan to sell their Entyvio knockoff, Takeda has said its regulatory protection on the ulcerative colitis and Crohn’s disease treatment extends into May 2026. But some patents on the drug expire in 2032, according to the company's most recent annual report (PDF).“Any biosimilar that seeks to launch prior to 2032 would need to address potential infringement and/or the validity of all relevant patents and therefore the exact timing of biosimilar entry is uncertain,” the Japanese company explained in the report.For the last three quarters of 2025, Takeda reported Entyvio worldwide sales were up by 7% at 744.5 billion Japanese yen ($4.98 billion), with U.S. sales accounting for 494.8 billion Japanese yen ($3.03 billion).

License out/inDrug ApprovalBiosimilar

18 Mar 2026

·www.biospace.com

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of Korea Samsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology INCHEON, Korea--(BUSINESS WIRE)-- #Entyvio --Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio 1 (vedolizumab). The other terms of the agreement remain confidential. Under the terms of the agreement, Samsung Bioepis will be responsible for development, regulatory registration in key markets, and manufacture of the biosimilars, while Sandoz will be responsible for commercialization in global markets, excluding China, Hong Kong, Taiwan, Macau, and Republic of Korea. “We are very pleased to expand our successful partnership with Sandoz and to secure commercialization agreement for multiple biosimilar assets that are in early-stage development. The agreement is a significant progress in improving access to biologic medicines for patients living with debilitating conditions, who have limited access to life-changing medicines,” said Kyung-Ah Kim, President and Chief Executive Officer, Samsung Bioepis. “At Samsung Bioepis, we will continue to demonstrate our enduring commitment to biosimilars by further strengthening our pipeline and widening their availability for patients and healthcare systems across the world.” SB36, under pre-clinical development at Samsung Bioepis, references Entyvio (vedolizumab) which is indicated for the treatment of adult patients with Crohn’s disease, ulcerative colitis and pouchitis. 2 The agreement builds on the global partnership between the two companies for PYZCHIVA ® (ustekinumab) established in September 2023. PYZCHIVA was first launched in Europe in July 2024 and in the United States in February 2025. In December 2025, the companies also signed an agreement for the commercialization of EPYSQLI™, a biosimilar to Soliris 3 (eculizumab), for the Middle East and Africa region. About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings, Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, endocrinology. For more information, please visit and follow us on LinkedIn and X . 1 Entyvio is a registered trademark of Takeda Pharmaceuticals 2 European Medicines Agency (EMA). Entyvio. Summary of Product Characteristics. Available at: Entyvio, INN-vedolizumab . Last accessed March 2026 3 Soliris is a registered trademark of Alexion Pharmaceuticals Contacts Media Contact Anna Nayun Kim, nayun86.kim@samsung.com Yoon Kim, yoon1.kim@samsung.com

License out/inDrug Approval

18 Mar 2026

·www.sandoz.com

Sandoz announces partnership agreement with Samsung Bioepis on up to five biosimilars, further expanding its leading pipeline to up to 32 assets

MEDIA RELEASE Agreement for up to five biosimilar assets, with potential for further collaboration; first asset to be vedolizumab biosimilar Collaboration builds on successful existing partnership; further strengthens Sandoz global position in biosimilars and could expand industry-leading pipeline to up to 32 assets Reinforces commitment to capture significant share of projected ~USD 320 billion biosimilar loss-of-exclusivity market opportunity over next decade1 Basel, March 18, 2026 – Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in affordable medicines, today announced a major license, development and commercialization partnership agreement with Samsung Bioepis Co., Ltd., marking a significant step to broaden patient access to high-quality biosimilar medicines worldwide. The agreement paves the way for the two companies to partner on up to five biosimilar assets. The first asset will be a vedolizumab biosimilar, which is in early-stage development. The reference medicine, Entyvio®* (vedolizumab), is used to treat adult patients with Crohn’s disease, ulcerative colitis or pouchitis2,3. Under the terms of the agreement, Sandoz will have exclusive rights to commercialize globally, except in China, Hong Kong, Taiwan, Macau and Republic of Korea. Samsung Bioepis will be responsible for development, regulatory submissions in key markets and manufacturing. Both companies have agreed to keep the financial details of the agreement confidential. The partnership could expand the leading Sandoz pipeline to up to 32 assets and reinforces its commitment to capturing a significant share of the projected global biosimilar loss-of-exclusivity market opportunity, estimated at around USD 320 billion over the next decade1. Richard Saynor, Chief Executive Officer, Sandoz, said: ”This partnership underscores our unwavering commitment to expanding access to affordable, high-quality medicines for patients worldwide. It is another important step toward capitalizing on the unprecedented biosimilar market opportunity over the next decade while also strengthening our partnership with Samsung Bioepis.” Today’s news builds on the successful global partnership between the two companies first established in September 2023 for Pyzchiva® (ustekinumab), which Sandoz launched in Europe in July 2024 and in the US in February 2025. The Pyzchiva collaboration is unaffected by the partnership announced today. In December 2025, the companies also signed an agreement for the commercialization of Epysqli™, a biosimilar to eculizumab (Soliris®**), for the Middle East and Africa region. Sandoz continues to develop its leading pipeline of biosimilar medicines, building on its experience as the pioneer and global leader with a portfolio of 13 molecules available in nearly 100 countries. *Entyvio® is a registered trademark of Takeda.**Soliris® is a registered trademark of Alexion. DISCLAIMER This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law. REFERENCES 1 Covers US and EU markets (2026–2035). Originator sales and LoE based on internal analysis of data from multiple subscription databases. Biosimilar data accessed in September 2025.2 European Medicines Agency (EMA). Entyvio. Summary of Product Characteristics. Available at: Entyvio, INN-vedolizumab. [Last accessed March 2026]3 FDA. Entyvio. Prescribing Information. Available at: ENTYVIO. [Last accessed March 2026] ABOUT SANDOZ Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in affordable medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 colleagues of 100 nationalities work together to ensure over one billion patients are reached by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 medicines addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. In 2026, Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing and 140 years of heritage. In 2025, Sandoz recorded net sales of USD 11.1 billion. CONTACTS Global Media Relations contacts Investor Relations contacts Global.MediaRelations@sandoz.com Investor.Relations@sandoz.com Alexis Kalomparis +41 79 279 0285 Craig Marks +44 78 1894 2383 Chris Lewis+49 174 244 9501 Tamara Hackl+41 79 790 5217 Gregor Rodehueser+49 170 574 3200 Silvia Siegfried+41 79 795 90 61

License out/in

100 Deals associated with Eculizumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03940	Eculizumab	L04AA25	DB01257

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
AQP4-IgG positive Neuromyelitis optica spectrum disorder	Australia	Alexion Pharmaceuticals, Inc.	20 Mar 2009
Atypical Hemolytic Uremic Syndrome	European Union	Alexion Europe SAS	20 Jun 2007
Atypical Hemolytic Uremic Syndrome	Iceland	Alexion Europe SAS	20 Jun 2007
Atypical Hemolytic Uremic Syndrome	Liechtenstein	Alexion Europe SAS	20 Jun 2007
Atypical Hemolytic Uremic Syndrome	Norway	Alexion Europe SAS	20 Jun 2007
Myasthenia Gravis	European Union	Alexion Europe SAS	20 Jun 2007
Myasthenia Gravis	Iceland	Alexion Europe SAS	20 Jun 2007
Myasthenia Gravis	Liechtenstein	Alexion Europe SAS	20 Jun 2007
Myasthenia Gravis	Norway	Alexion Europe SAS	20 Jun 2007
Neuromyelitis Optica	European Union	Alexion Europe SAS	20 Jun 2007
Neuromyelitis Optica	Iceland	Alexion Europe SAS	20 Jun 2007
Neuromyelitis Optica	Liechtenstein	Alexion Europe SAS	20 Jun 2007
Neuromyelitis Optica	Norway	Alexion Europe SAS	20 Jun 2007
Hemoglobinuria, Paroxysmal	United States	Alexion Pharmaceuticals, Inc.	16 Mar 2007

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Delayed Graft Function	Phase 3	Germany	Alexion Pharmaceuticals, Inc.	25 Jun 2014
AQP4-IgG positive Optic Neuritis	Phase 3	United States	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Japan	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Argentina	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Australia	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Croatia	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Czechia	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Denmark	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Germany	Alexion Pharmaceuticals, Inc.	11 Apr 2014
AQP4-IgG positive Optic Neuritis	Phase 3	Hong Kong	Alexion Pharmaceuticals, Inc.	11 Apr 2014

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2025	Not Applicable	Atypical Hemolytic Uremic Syndrome \| Hemoglobinuria, Paroxysmal \| Pancytopenia ... View more	96	Eculizumab	cludoucepg(dhgaqihntd) = jzvnpgkjjk rhrkbgoydq (wzsqbnouad )	Positive	06 Dec 2025
				Eculizumab (immune competent cohort)	lrehwnszom(mslcedfego) = eijxqkpuch nsoggbtkyn (eqzkjxnasz )
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	31	Iptacopan	cnhskldfxk(qdvlamhhcb) = mcftbwfbbw rwupecekfg (ewnnqdaoud ) View more	Positive	06 Dec 2025
				Eculizumab	cnhskldfxk(qdvlamhhcb) = eyljoxthjl rwupecekfg (ewnnqdaoud ) View more
ASH2025	Not Applicable	Thrombotic Microangiopathies	21	Eculizumab	iyvahkubpf(chkrpshihv) = rbyocehbnr jhszokpfkc (cxdhpqemrf ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal	87	eculizumab	reoqkvwygg(vgaikqpnfc) = vkmotwpymx jhssnbmstq (rjnqsatctg ) View more	Positive	06 Dec 2025
				ravulizumab	reoqkvwygg(vgaikqpnfc) = kzqwdlvaih jhssnbmstq (rjnqsatctg ) View more
ASH2025	Not Applicable	Hemoglobinuria, Paroxysmal \| Myeloproliferative Disorders	11	Eculizumab	lmqxdznqsx(awggpuzywy) = Sepsis as the cause of death in 3 cases knaehmcfxq (mbrjndwasn )	Negative	06 Dec 2025
NCT05966467 (NMO SPOTLIGHT Registry, ECTRIMS2025 \| Company_Website) Manual	Not Applicable	AQP4-IgG positive Neuromyelitis optica spectrum disorder AQP4-IgG	56	ALXN-C5IT (eculizumab or ravulizumab)	xpupequujg(dybegdzqsv) = ejsqojecma yyjtmqdbmb (ruglhqbchh, 0.00 - 0.05) View more	Positive	09 Sep 2025
				ALXN-C5IT (eculizumab or ravulizumab) (switched from rituximab)	xpupequujg(dybegdzqsv) = vxjjtmnaga yyjtmqdbmb (ruglhqbchh ) View more
PB2827 (EHA2025)	Not Applicable	Hemoglobinuria, Paroxysmal	52	Eculizumab	pnlqwmmtrz(rynorgular) = occurred in 30.8% ogdixalyrh (yhsfuwohyd ) View more	-	14 May 2025
S34.006 (AAN2025)	Not Applicable	Myasthenia Gravis anti-acetylcholine receptor antibody-positive (AChR-Ab+)	254	Eculizumab	dzjrvgginw(fnuyhpcnqi) = 40.5% experienced adverse drug reactions (ADRs) zquopjvvcx (ooednljhva ) View more	Positive	07 Apr 2025
NCT05966467 (NMO SPOTLIGHT Registry, AAN2025)	Not Applicable	AQP4-IgG positive Neuromyelitis optica spectrum disorder	30	Eculizumab	ixkyfgrcsq(ptphojgcyp) = wzmanplwwk vpjfwfhxop (jemobdlbam, 24.0 - 49.7)	Positive	07 Apr 2025
				Ravulizumab	ixkyfgrcsq(ptphojgcyp) = igpadlkslq vpjfwfhxop (jemobdlbam, 0.7 - 1.3)
ASH2024	Not Applicable	Atypical Hemolytic Uremic Syndrome	-	Eculizumab	pphcnuvwkb(swmmxxnzyi) = ylqcfdhbdt vvgbxevfic (vcaqkjdhdi, 230.0 - 362.0) View more	-	08 Dec 2024
				Ravulizumab	qkgrbdachl(rzyrjlcylo) = ncycqlvser fjhaqhiuho (ofmgytotzc, 11.5% - 36.4%)

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Eculizumab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation